A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Inclusion Criteria

• Subject who has histologically confirmed and documented B-cell lymphoma (eg, follicular, diffuse large B-cell, mantle cell, small lymphocytic, or Hodgkin lymphoma) and chronic lymphocytic leukemia.
• Subject who has high-risk chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
• Subject who was previously treated with at least one prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy.
• Subject who has the Eastern Cooperative Oncology Group performance status of 0, 1, or 2.
• Subject who is willing and able to undergo biopsy.
• Subject who has documented active relapsed or refractory disease requiring therapeutic intervention.
• Subject with lymphoma who has measurable disease (≥ 2.0 cm in its longest dimension by computed tomography) or chronic lymphocytic leukemia in need of treatment.
• Subject who fulfills the laboratory requirements as per protocol

Exclusion Criteria

• Subject who has central nervous system (CNS) or meningeal involvement by lymphoma.
• Subject who has any histopathologic finding consistent with myelodysplastic syndrome on bone marrow studies.
• Subject who received any prior monoclonal antibodies against programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) and/or any prior:
• Arm A only: drugs with immunomodulatory and other properties (eg, lenalidomide, thalidomide);
• Arm B only: ibrutinib or other Bruton's tyrosine kinase (BTK) inhibitor;
• Arms C only: bendamustine
• Subject who has active auto-immune disease.
• Subject who has history of organ transplant or allogeneic hematopoietic stem cell transplantation.
• Subject who is seropositive for or active viral infection with hepatitis B virus (HBV) (hepatitis B surface antigen [HBsAg] positive and/or detectable viral DNA)
• Subject who has known seropositivity for or active infection for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
• Subject who has history of primary immunodeficiency or tuberculosis.
• Subject who other invasive malignancy within 2 years (5 years for Arm A) except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast, or incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) that has/have been surgically cured.